JP2023526428A5 - - Google Patents

Info

Publication number
JP2023526428A5
JP2023526428A5 JP2022570534A JP2022570534A JP2023526428A5 JP 2023526428 A5 JP2023526428 A5 JP 2023526428A5 JP 2022570534 A JP2022570534 A JP 2022570534A JP 2022570534 A JP2022570534 A JP 2022570534A JP 2023526428 A5 JP2023526428 A5 JP 2023526428A5
Authority
JP
Japan
Prior art keywords
polypeptide
protease
antigen
subunit
life extension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526428A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/033014 external-priority patent/WO2021236676A1/en
Publication of JP2023526428A publication Critical patent/JP2023526428A/ja
Publication of JP2023526428A5 publication Critical patent/JP2023526428A5/ja
Priority to JP2025227145A priority Critical patent/JP2026031678A/ja
Pending legal-status Critical Current

Links

JP2022570534A 2020-05-19 2021-05-18 活性化可能なil-12ポリペプチド及びその使用方法 Pending JP2023526428A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025227145A JP2026031678A (ja) 2020-05-19 2025-12-03 活性化可能なil-12ポリペプチド及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063027276P 2020-05-19 2020-05-19
US63/027,276 2020-05-19
PCT/US2021/033014 WO2021236676A1 (en) 2020-05-19 2021-05-18 Activatable il-12 polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025227145A Division JP2026031678A (ja) 2020-05-19 2025-12-03 活性化可能なil-12ポリペプチド及びその使用方法

Publications (2)

Publication Number Publication Date
JP2023526428A JP2023526428A (ja) 2023-06-21
JP2023526428A5 true JP2023526428A5 (cg-RX-API-DMAC7.html) 2024-05-24

Family

ID=76375661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022570534A Pending JP2023526428A (ja) 2020-05-19 2021-05-18 活性化可能なil-12ポリペプチド及びその使用方法
JP2025227145A Pending JP2026031678A (ja) 2020-05-19 2025-12-03 活性化可能なil-12ポリペプチド及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025227145A Pending JP2026031678A (ja) 2020-05-19 2025-12-03 活性化可能なil-12ポリペプチド及びその使用方法

Country Status (11)

Country Link
US (1) US20240043488A1 (cg-RX-API-DMAC7.html)
EP (1) EP4153612A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023526428A (cg-RX-API-DMAC7.html)
KR (1) KR20230012564A (cg-RX-API-DMAC7.html)
CN (1) CN116096738A (cg-RX-API-DMAC7.html)
AU (1) AU2021276337A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023288A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178657A1 (cg-RX-API-DMAC7.html)
IL (1) IL298295A (cg-RX-API-DMAC7.html)
MX (1) MX2022014411A (cg-RX-API-DMAC7.html)
WO (1) WO2021236676A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
EP4004026A4 (en) * 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
EP4372000B1 (en) 2022-02-15 2026-06-17 Tagworks Pharmaceuticals B.V. Masked il12 protein
AU2023248470A1 (en) * 2022-04-07 2024-10-03 Werewolf Therapeutics Inc. Il-12 prodrugs
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
AR131624A1 (es) * 2023-01-18 2025-04-16 Chugai Pharmaceutical Co Ltd Citoquina activada por proteasa
WO2024211877A2 (en) * 2023-04-06 2024-10-10 Werewolf Therapeutics, Inc. Il-12 prodrugs, methods of use and pharmaceutical compositions
WO2025072450A1 (en) 2023-09-26 2025-04-03 Werewolf Therapeutics, Inc. Enhanced adoptive cell therapy
WO2026072455A1 (en) 2024-09-26 2026-04-02 Werewolf Therapeutics, Inc. Single domain human serum albumin antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110728A2 (en) 2005-04-12 2006-10-19 The Uab Research Foundation Immunogenic cmv tegument aggregates
EP3511340B1 (en) * 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
US10472816B2 (en) 2017-07-26 2019-11-12 Justin Griebel Backflow valve assembly
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
WO2021062406A1 (en) * 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
MX2022011676A (es) * 2020-03-23 2023-03-08 Zymeworks Bc Inc Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.

Similar Documents

Publication Publication Date Title
JP2019513014A5 (cg-RX-API-DMAC7.html)
JP2021087429A5 (cg-RX-API-DMAC7.html)
US20250163153A1 (en) Release segments and binding compositions comprising same
JP7490853B2 (ja) 拘束され、条件的に活性化された結合タンパク質
EP2609112B1 (en) Activatable bispecific antibodies
US20210355219A1 (en) Conditionally activated target-binding molecules
US20220267400A1 (en) Il-2 cytokine prodrugs comprising a cleavable linker
JP7707360B2 (ja) 拘束され、条件的に活性化された結合タンパク質
JP2023552812A5 (cg-RX-API-DMAC7.html)
JP2021523741A5 (cg-RX-API-DMAC7.html)
JP2023511074A (ja) 切断可能リンカーを含むサイトカインプロドラッグ
JP7855148B2 (ja) 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
JP2023540533A (ja) ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物
CN115003693A (zh) 多肽、蛋白质复合物及其制造方法
US12590159B2 (en) Compositions targeting epidermal growth factor receptor and methods for making and using the same
JP2025511713A5 (cg-RX-API-DMAC7.html)
JP2025511187A5 (cg-RX-API-DMAC7.html)
CN118556074A (zh) 接头多肽
JP2024531338A5 (cg-RX-API-DMAC7.html)
JP2024531338A (ja) 活性化可能インターフェロンポリペプチド及びその使用方法
JP2024542978A5 (cg-RX-API-DMAC7.html)
JP2025511190A5 (cg-RX-API-DMAC7.html)
JPWO2023068377A5 (cg-RX-API-DMAC7.html)
RU2020123264A (ru) Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
WO2026024863A2 (en) Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists